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Dear Editor, 
Post-transplant lymphoproliferative disorder (PTLD) with central nervous system 
(CNS) involvement is associated with poor outcomes (1, 2). Patients undergoing 
kidney transplantation (KTx) have the highest risk of primary CNS (PCNS)-PTLD 
development, and the development rate is reportedly increasing (1). However, 
clinical information about PCNS-PTLD has been limited, especially in Asian 
populations, because of its rarity. Herein, we reviewed the records of patients with 
PCNS-PTLD by using data from a multicenter observational cohort study of 
patients undergoing KTx (The Japan Academic Consortium of KTx; JACK: 
UMIN00001832). We included 2020 consecutive patients undergoing KTx at 3 
transplant centers (Tokyo Women’s Medical University, Toda-Chuo General 
Hospital, and Okubo Hospital) between 1986 and 2016. To the best of our 
knowledge, the present study is the first to highlight PCNS-PTLD following KTx 
in Asian population. 
PTLD developed in 16 patients, including 6 cases of PCNS-PTLD. The 
clinicopathological characteristics are shown in Table 1. The study revealed 
several interesting findings, including a higher rate of PCNS-PTLD development 
among the PTLD cases than was expected (6 of 16 patients, 37.5%), and very 
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late-onset development (mean time from transplantation to diagnosis, 116.5 
months in 3 of 6 patients, 50.0%) compared to a previous study (2). We 
speculated that this tendency might be caused by an unidentified genome type 
that is specific to the Japanese population with regard to Epstein-Barr virus (EBV) 
infection and the mechanism of EBV-associated carcinogenesis. We found that 
60% of PCNS-PTLD cases (3 of 5 patients; patient No.1 was not considered) 
were associated with EBV. Lustberg et al. (3) reported that specific human 
leukocyte antigen types display novel susceptibility factors for PTLD in EBV-
seropositive and EBV-seronegative individuals. Moreover, PCNS-PTLD was 
commonly diagnosed as EBV-associated lymphoma or B-cell lymphoma 
(including diffuse large B-cell lymphoma)(1, 2). Indeed, in this study, such cases 
were observed in 5 of 6 patients (83.3%). Fink et al. (4) suggested that EBV has 
a major impact on cellular microRNA expression in PTLD, and that EBV-
associated PCNS-PTLD could possibly have a different mechanism for the 
activation of tumor cell growth and inhibition of apoptosis than systematic PTLD 
did, resulting in a higher frequency of EBV-association in PCNS-PTLD compared 
to that of systematic PTLD. Thus, there might be a genomic association specific 
to Japanese people, considering PCNS-PTLD development. 
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Finally, the immunosuppressive regimen administered at diagnosis was 
homogeneous, and included mycophenolate mofetil (MMF). MMF use has been 
previously suggested as a risk factor for PCNS-PTLD development, as the deep 
immunosuppressive effect is suspected to influence the carcinogenic mechanism 
(1). Indeed, in an international report on PCNS-PTLD, MMF usage was frequently 
observed (82%)(2). In this study, unfortunately, we could not find the association 
between MMF and carcinogenesis because the trough level of MMF was missing. 
Meanwhile, we found that trough level of calcineurin inhibitor did not affect PCNS-
PTLD development (data not shown); however, these data were strongly limited 
due to the small number of patients.  
In summary, PCNS-PTLD can develop long after KTx, even after ≥10 years, and 
the development rate may be higher than expected. Thus, we should monitor 
disease development for a long time, especially when MMF is used in the 
immunosuppressive regimen. We believe that the present data from a large 
multicenter Japanese database can provide new information for physicians.  
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Table 1: Clinicopathological characteristics  
Pt. Sex 
Age 
at Dx 
(y) 
Tx to 
Dx 
(mo) 
Year 
at Dx 
Donor Initial IS IS at Dx 
Pre-Tx 
EBV IgG 
Pathology 
EBV-
associated 
tumor 
Treatment 
Patient 
outcome 
Patient 
survival 
(mo) 
Graft 
outcome 
Graft 
survival 
(mo) 
1 M 27 7.76 1989 Living 
CYA/AZ/MP/
ALG/DSG 
CYA/AZ/
MP 
Positive ML N/A 
RI, 
radiotherapy 
Died 1 Function 1 
2 M 55 250.8 2011 Deceased CYA/MZ/MP 
FK/MMF/
MP 
N/A 
Polymorphic 
B-cell 
lymphoma 
Yes RI, CYVE CR 44.4 Loss 2.89 
3 M 65 131.6 2011 Deceased FK/MMF/MP 
FK/MMF/
MP 
Positive DLBCL Yes 
RI, R-CHOP, 
HD-MTX 
CR 58.4 Function 58.4 
4 M 67 38.3 2013 Deceased 
FK/MMF/MP/
RTX 
FK/MMF/
MP 
Positive DLBCL Yes 
RI, surgery, 
radiotherapy 
Alive with 
brain 
damage 
34.1 Function 34.1 
5 M 79 45.0 2015 Living 
FK/MMF/MP/
RTX 
FK/MMF/
MP 
Positive DLBCL No RI, R-CHOP Died 6.8 Function 6.8 
6 F 50 225.6 2015 Living FK/AZ/MP 
FK/MMF/
MP 
Positive DLBCL No RI, MTX 
Alive with 
brain 
damage 
8.71 Function 8.71 
Pt, patient; Dx, diagnosis; Tx, Transplantation; IS, immunosuppression; EBV, Epstein-Barr virus; IgG, immunoglobulin; CYA, cyclosporine; AZ, azathioprine; MP, 
methylprednisolone; ALG, antilymphocyte globulin; DSG, deoxyspergualine; MZ, mizoribine; FK, tacrolimus; MMF, mycophenolate mofetil; RTX, rituximab; N/A, not 
applicable; ML, malignant lymphoma; DLBCL, diffuse large B-cell lymphoma; RI, reduced immunosuppression; CYVE, cytarabine-etoposide; R-CHOP, rituximab-
cyclophosphamide-doxorubicin-vincristine-predonisolone; HD-MTX, high-dose methotrexate; MTX, methotrexate; CR, complete response  
 
